Pfizer will charge $1,390 for a five-day course of Paxlovid on the commercial market, increasing the price from the pandemic-era rate it had been giving to the US government.
The drugmaker last week announced the end of a program where US health authorities bought and were responsible for distributing the Paxlovid doses at a price of $530 per course. Many of those pills, cleared under emergency use authorization, will be returned to the drugmaker. Because of that, and because of declining demand for Covid products overall, Pfizer is embarking on a $3.5 billion cost-cutting program this year and next.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.